CoChat
Sign Up
Cited by 28Adenosine and Purinergic SignalingBone fractures and treatmentsBone Metabolism and Diseases

The Adenosine A2A Receptor Agonist Accelerates Bone Healing and Adjusts Treg/Th17 Cell Balance through Interleukin 6

Open access
Zheng, Xi, Wang, Dong·2020·BioMed Research International
DOI 10.1155/2020/2603873PMC PMC7195650
Open this paper in CoChat — free accountOpen PDF

Abstract

The aim of this study was to explore the effect of adenosine A2A receptor agonists on fracture healing and the regulation of the immunity system after bone fracture. We implanted fibrin gel containing adenosine A2A receptor agonist CGS 21680/inhibitor ZM 241385/saline locally in rat tibial fracture models, finding that the adenosine A2A receptor agonist could promote fracture healing. At the same time, the adenosine A2A receptor agonist decreased the level of IL‐6 in blood and the fracture area, increased Treg cells, and decreased Th17 cells in blood of bone fracture rats. Further, tibial fracture rats implanted with the adenosine A2A receptor agonist gel were injected with IL‐6. We found that IL‐6 could reverse the effect of adenosine A2A receptor agonists on fracture healing and Treg/Th17 cells in blood. Through the above results, we believe that the adenosine A2A receptor agonist can promote fracture healing and regulate Treg/Th17 cells in blood of rats with fractures. These effects are related to IL‐6.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2020/2603873

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Decreasing Th17 cells and increasing Tregs improved bone repair by inhibiting pro-inflammatory effects of T cells such as IL-6 production.

    “Recent work has identified that altering the Th17/Treg ratio balance impacts healing—decreasing Th17 cells and increasing Tregs improved bone repair by inhibiting pro-inflammatory effects of T cells such as IL-6 production [71].”

    From Osteoimmunology of Fracture Healing. (2024) · cites this paper as [71]

    The Results (§§3.2 and 3.4; page unavailable) report that A2A receptor agonist treatment lowered IL-6, increased blood Tregs, decreased blood Th17 cells, and improved fracture healing in rats. The paper does not establish that changing the Th17/Treg balance improved repair *by inhibiting IL-6 production by T cells*; its Discussion (§4) describes the relationship between those cells and healing as a possibility for further study. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 49

  1. [1]Toosi S. Behravan N. Behravan J. Nonunion fractures, mesenchymal stem cells and bone tissue engineering Journal of Biomedical Materials Research. Part A 2018 106 9 2552 2562 10.1002/jbm.a.36433 2-s2.0-85046549594 29689623 · DOI
  2. [2]Dumic-Cule I. Peric M. Kucko L. Grgurevic L. Pecina M. Vukicevic S. Bone morphogenetic proteins in fracture repair International Orthopaedics 2018 42 11 2619 2626 10.1007/s00264-018-4153-y 2-s2.0-85053639354 30219967 · DOI
  3. [3]Trajanoska K. Schoufour J. D. de Jonge E. A. L. Fracture incidence and secular trends between 1989 and 2013 in a population based cohort: the Rotterdam study Bone 2018 114 116 124 10.1016/j.bone.2018.06.004 2-s2.0-85048706301 29885926 · DOI
  4. [4]Mcginty T. Mallon P. W. G. Fractures and the gut microbiome Current Opinion in HIV and AIDS 2018 13 1 28 37 10.1097/COH.0000000000000425 2-s2.0-85036640845 29049037 · DOI
  5. [5]Veronese N. Maggi S. Epidemiology and social costs of hip fracture Injury 2018 49 8 1458 1460 10.1016/j.injury.2018.04.015 2-s2.0-85046120504 29699731 · DOI
  6. [6]Brinker M. R. Hanus B. D. Sen M. O'Connor D. P. The devastating effects of tibial nonunion on health-related quality of life The Journal of Bone and Joint Surgery. American Volume 2013 95 24 2170 2176 10.2106/JBJS.L.00803 2-s2.0-84894380600 24352770 · DOI
  7. [7]Fong K. Truong V. Foote C. J. Predictors of nonunion and reoperation in patients with fractures of the tibia: an observational study BMC Musculoskeletal Disorders 2013 14 p. 103 10.1186/1471-2474-14-103 2-s2.0-84875200200 23517574 PMC3614478 · DOI
  8. [8]Konda S. Saleh H. Fisher N. Egol K. A. Posterolateral bone grafting for distal tibia nonunion Journal of Orthopaedic Trauma 2017 31 Supplement 3 p. S16 10.1097/BOT.0000000000000902 2-s2.0-85047298389 28697075 · DOI
  9. [9]Zura R. Mehta S. Della Rocca G. J. Steen R. G. Biological risk factors for nonunion of bone fracture JBJS Reviews 2016 4 1 p. 1 10.2106/JBJS.RVW.O.00008 2-s2.0-84994171691 27490008 · DOI
  10. [10]Maisani M. Sindhu K. R. Fenelon M. Prolonged delivery of BMP-2 by a non-polymer hydrogel for bone defect regeneration Drug Delivery and Translational Research 2018 8 1 178 190 10.1007/s13346-017-0451-y 2-s2.0-85040061775 29192408 · DOI
  11. [11]Killington K. Mafi R. Mafi P. Khan W. S. A systematic review of clinical studies investigating mesenchymal stem cells for fracture non-union and bone defects Current Stem Cell Research & Therapy 2018 13 4 284 291 10.2174/1574888X12666170915121137 2-s2.0-85046735681 28914208 · DOI
  12. [12]Rutten S. van den Bekerom M. P. J. Sierevelt I. N. Nolte P. A. Enhancement of bone-healing by low-intensity pulsed Ultrasound JBJS Reviews 2016 4 3 p. 1 10.2106/JBJS.RVW.O.00027 2-s2.0-84994128182 27500435 · DOI
  13. [13]Madariaga H. M. Riella L. V. Chronic allograft injury: an overview of pathogenesis and treatment strategies Contributions to Nephrology 2017 190 168 180 10.1159/000468963 2-s2.0-85020239040 28535528 · DOI
  14. [14]Merola J. Jane-Wit D. D. Pober J. S. Recent advances in allograft vasculopathy Current Opinion in Organ Transplantation 2017 22 1 1 7 10.1097/MOT.0000000000000370 2-s2.0-85000580097 27898462 PMC5391675 · DOI
  15. [15]Azi M. L. Aprato A. Santi I. Kfuri, Mauricio, Jr Masse A. Joeris A. Autologous bone graft in the treatment of post-traumatic bone defects: a systematic review and meta-analysis BMC Musculoskeletal Disorders 2016 17 1 1 10 10.1186/s12891-016-1312-4 2-s2.0-84994558665 27829447 PMC5103502 · DOI
  16. [16]Poon B. Kha T. Tran S. Dass C. R. Bone morphogenetic protein-2 and bone therapy: successes and pitfalls The Journal of Pharmacy and Pharmacology 2016 68 2 139 147 10.1111/jphp.12506 2-s2.0-84958759266 26727402 · DOI
  17. [17]Croes M. Kruyt M. C. Groen W. M. Interleukin 17 enhances bone morphogenetic protein-2-induced ectopic bone formation Scientific Reports 2018 8 1 p. 7269 10.1038/s41598-018-25564-9 2-s2.0-85046840692 29740080 PMC5940874 · DOI
  18. [18]Carragee E. J. Hurwitz E. L. Weiner B. K. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned The Spine Journal 2011 11 6 471 491 10.1016/j.spinee.2011.04.023 2-s2.0-79959950769 21729796 · DOI
  19. [19]Kinsella C. R. Jr. Cray J. J. Durham E. L. Recombinant human bone morphogenetic protein-2-induced craniosynostosis and growth restriction in the immature skeleton Plastic and Reconstructive Surgery 2011 127 3 1173 1181 10.1097/PRS.0b013e318205f2b4 2-s2.0-79952759036 21364420 · DOI
  20. [20]Lopez C. D. Bekisz J. M. Corciulo C. Local delivery of adenosine receptor agonists to promote bone regeneration and defect healing Advanced Drug Delivery Reviews 2019 146 240 247 10.1016/j.addr.2018.06.010 2-s2.0-85048857997 29913176 · DOI
  21. [21]Wang L. Wan H. Tang W. Critical roles of adenosine A2A receptor in regulating the balance of Treg/Th17 cells in allergic asthma The Clinical Respiratory Journal 2018 12 1 149 157 10.1111/crj.12503 2-s2.0-84977103653 27216911 · DOI
  22. [22]Liang D. Zuo A. Shao H. Chen M. Kaplan H. J. Sun D. Anti-inflammatory or proinflammatory effect of an adenosine receptor agonist on the Th17 autoimmune response is inflammatory environment-dependent Journal of Immunology 2014 193 11 5498 5505 10.4049/jimmunol.1401959 2-s2.0-84912550490 25367119 PMC4299924 · DOI
  23. [23]Wang M. Tian T. Yu S. He N. Ma D. Th17 and Treg cells in bone related diseases Clinical & Developmental Immunology 2013 2013 1 1 10 10.1155/2013/203705 2-s2.0-84885573369 24187560 PMC3800633 · DOI
  24. [24]Kimura A. Kishimoto T. IL-6: regulator of Treg/Th17 balance European Journal of Immunology 2010 40 7 1830 1835 10.1002/eji.201040391 2-s2.0-77954096689 20583029 · DOI
  25. [25]Haskó G. Antonioli L. Cronstein B. N. Adenosine metabolism, immunity and joint health Biochemical Pharmacology 2018 151 307 313 10.1016/j.bcp.2018.02.002 2-s2.0-85042125538 29427624 PMC5899962 · DOI
  26. [26]Ansari M. A. Nadeem A. Attia S. M. Bakheet S. A. Raish M. Ahmad S. F. Adenosine A2A receptor modulates neuroimmune function through Th17/retinoid-related orphan receptor gamma t (RORγt) signaling in a BTBR T+ Itpr3tf/J mouse model of autism Cellular Signalling 2017 36 14 24 10.1016/j.cellsig.2017.04.014 2-s2.0-85018637151 28438638 · DOI
  27. [27]Rubalskii E. Ruemke S. Salmoukas C. Fibrin glue as a local drug-delivery system for bacteriophage PA5 Scientific Reports 2019 9 1 1 8 10.1038/s41598-018-38318-4 2-s2.0-85061592728 30765740 PMC6376040 · DOI
  28. [28]Yoshida H. Yamaoka Y. Shinoyama M. Kamiya A. Novel drug delivery system using autologous fibrin glue--release properties of anti-cancer drugs Biological & Pharmaceutical Bulletin 2000 23 3 371 374 10.1248/bpb.23.371 2-s2.0-0034034738 10726900 · DOI
  29. [29]Kawai H. Fibrin glue-minocycline combination as a sustained release for the prevention of postoperative alveolar air leak in thoracoscopic lung resections The Thoracic and Cardiovascular Surgeon 2017 65 5 392 394 10.1055/s-0037-1598622 2-s2.0-85014100732 28249342 · DOI
  30. [30]Spicer P. P. Mikos A. G. Fibrin glue as a drug delivery system Journal of Controlled Release 2010 148 1 49 55 10.1016/j.jconrel.2010.06.025 2-s2.0-78649529351 20637815 PMC3005546 · DOI
  31. [31]Tawonsawatruk T. Kelly M. Simpson H. Evaluation of native mesenchymal stem cells from bone marrow and local tissue in an atrophic nonunion model Tissue Engineering. Part C, Methods 2014 20 6 524 532 10.1089/ten.TEC.2013.0465 2-s2.0-84901018639 24147916 · DOI
  32. [32]Hao C. Wang Y. Shao L. Liu J. Chen L. Zhao Z. Local injection of bone mesenchymal stem cells and fibrin glue promotes the repair of bone atrophic nonunion in vivo Advances in Therapy 2016 33 5 824 833 10.1007/s12325-016-0329-2 2-s2.0-84964334325 27098172 · DOI
  33. [33]Murakami H. Nakasa T. Ishikawa M. Adachi N. Ochi M. Autologous bone grafts with MSCs or FGF-2 accelerate bone union in large bone defects Journal of Orthopaedic Surgery and Research 2016 11 1 p. 105 10.1186/s13018-016-0442-6 2-s2.0-84988815164 27669690 PMC5037630 · DOI
  34. [34]Zura R. Xiong Z. Einhorn T. Epidemiology of fracture nonunion in 18 human bones JAMA Surgery 2016 151 11, article e162775 10.1001/jamasurg.2016.2775 2-s2.0-84997525236 27603155 · DOI
  35. [35]Kostenuik P. Mirza F. M. Fracture healing physiology and the quest for therapies for delayed healing and nonunion Journal of Orthopaedic Research 2017 35 2 213 223 10.1002/jor.23460 2-s2.0-85007010461 27743449 PMC6120140 · DOI
  36. [37]Mediero A. Cronstein B. N. Adenosine and bone metabolism Trends in Endocrinology and Metabolism 2013 24 6 290 300 10.1016/j.tem.2013.02.001 2-s2.0-84878232571 23499155 PMC3669669 · DOI · Paper page
  37. [38]Bekisz J. M. Flores R. L. Witek L. Dipyridamole enhances osteogenesis of three-dimensionally printed bioactive ceramic scaffolds in calvarial defects Journal of Cranio-Maxillo-Facial Surgery 2018 46 2 237 244 10.1016/j.jcms.2017.11.011 2-s2.0-85039548725 29292126 PMC5803375 · DOI
  38. [39]Cronstein B. N. Sitkovsky M. Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases Nature Reviews Rheumatology 2017 13 1 41 51 10.1038/nrrheum.2016.178 2-s2.0-84994644848 27829671 PMC5173391 · DOI
  39. [40]Boros D. Thompson J. Larson D. F. Adenosine regulation of the immune response initiated by ischemia reperfusion injury Perfusion 2016 31 2 103 110 10.1177/0267659115586579 2-s2.0-84958953530 25987550 · DOI
  40. [41]Bortoluzzi A. Vincenzi F. Govoni M. A2A adenosine receptor upregulation correlates with disease activity in patients with systemic lupus erythematosus Arthritis Research & Therapy 2016 18 p. 192 10.1186/s13075-016-1089-8 2-s2.0-84983637876 27566294 PMC5002091 · DOI
  41. [42]Baht G. S. Vi L. Alman B. A. The role of the immune cells in fracture healing Current Osteoporosis Reports 2018 16 2 138 145 10.1007/s11914-018-0423-2 2-s2.0-85044442887 29508143 PMC5866272 · DOI · Paper page
  42. [43]El-Jawhari J. J. Jones E. Giannoudis P. V. The roles of immune cells in bone healing; what we know, do not know and future perspectives Injury 2016 47 11 2399 2406 10.1016/j.injury.2016.10.008 2-s2.0-84994102612 27809990 · DOI
  43. [44]Toben D. Schroeder I. el Khassawna T. Fracture healing is accelerated in the absence of the adaptive immune system Journal of Bone and Mineral Research 2011 26 1 113 124 10.1002/jbmr.185 2-s2.0-78650938516 20641004 · DOI · Paper page
  44. [45]Sun G. Wang Z. Ti Y. STAT3 promotes bone fracture healing by enhancing the FOXP3 expression and the suppressive function of regulatory T cells APMIS 2017 125 8 752 760 10.1111/apm.12706 2-s2.0-85019064318 28493494 · DOI
  45. [46]Compston J. HIV infection and osteoporosis BoneKEy Reports 2015 4 p. 636 10.1038/bonekey.2015.3 PMC4325555 25709813 · DOI
  46. [47]Yin M. T. Falutz J. How to predict the risk of fracture in HIV? Current Opinion in HIV and AIDS 2016 11 3 261 267 10.1097/COH.0000000000000273 2-s2.0-84959230654 26918651 PMC5399770 · DOI
  47. [48]Jiang H. Ti Y. Wang Y. Downregulation of regulatory T cell function in patients with delayed fracture healing Clinical and Experimental Pharmacology & Physiology 2018 45 5 430 436 10.1111/1440-1681.12902 2-s2.0-85040737655 29215756 · DOI
  48. [49]Prystaz K. Kaiser K. Kovtun A. Distinct effects of IL-6 classic and trans-signaling in bone fracture healing The American Journal of Pathology 2018 188 2 474 490 10.1016/j.ajpath.2017.10.011 2-s2.0-85043493019 29146294 · DOI · Paper page
  49. [50]Huang L. Liu S. Song T. Zhang W. Fan J. Liu Y. Blockade of interleukin 6 by rat anti-mouse interleukin 6 receptor antibody promotes fracture healing Biochemistry 2017 82 10 1193 1199 10.1134/S0006297917100121 2-s2.0-85031723291 29037140 · DOI

Cited by

Sorted by citations

  • Osteoimmunology of Fracture Healing.

    Molitoris, K. H., Huang, M., & Baht, G. S. (2024) · Current Osteoporosis Reports · doi:10.1007/s11914-024-00869-z · Cited by 84 · see citing works

    “Recent work has identified that altering the Th17/Treg ratio balance impacts healing—decreasing Th17 cells and increasing Tregs improved bone repair by inhibiting pro-inflammatory effects of T cells such as IL-6 production [71].”
    Background

Authors
Zheng, X., & Wang, D.
Affiliations
Capital Medical University (CN)
Corresponding author
Wang, Dong
ORCID
Venue
BioMed Research International
Publisher
Wiley
Published
2020-01
Volume
2020
Issue
1
Pages
2603873-2603873
ISSN
  • 1110-7243 (ISSN-L)
  • 2314-6133
  • 2314-6141
DOI
10.1155/2020/2603873
PMC
PMC7195650
OpenAlex
W3017426237
Cited by
28
References
1
Citations by year
2026: 4 · 2025: 2 · 2024: 4 · 2023: 7 · 2022: 7 · 2021: 4
FWCI
2.83
Type
journal article
Language
en
Open access
Licence
Locations
  • BioMed Research International (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
  • Health Sciences › Medicine › Epidemiology › Bone fractures and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords
adenosine A2A receptor agonist, CGS 21680, ZM241385, fracture healing, bone regeneration, interleukin-6, regulatory T cells, Th17 cells, Th17/Treg balance, tibial fractures, local drug delivery, immunomodulation
MeSH terms
Adenosine, Animals, Disease Models, Animal, Female, Phenethylamines, Tibial Fractures, Interleukin-6, Fracture Healing, Rats, Sprague-Dawley, Receptor, Adenosine A2A, T-Lymphocytes, Regulatory, Rats, Th17 Cells, Adenosine A2 Receptor Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review